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Risk stratification is central to the management of normo-
tensive patients with haemodynamically stable acute pul-
monary embolism. By assigning each patient to a specific 
risk class, the physician is guided in the choice of the most 
appropriate management modality, including but not lim-
ited to the timing, type and setting of treatment.1,2
At the high end of the severity spectrum, treatment of 
pulmonary embolism is aimed to minimize the risk of 
haemodynamic deterioration and to prevent death. The 
management of these patients rests on close monitoring, 
ideally in a higher-intensity setting, as they may need 
advanced reperfusion therapies if the situation escalates. At 
the opposite end are patients at the lowest risk of early 
death. In the foreground, in this case, is the maximization 
of the patient’s satisfaction and quality of life, as well as 
reasonable governance of health resources. If all require-
ments for their safety are met, these patients can be consid-
ered for early discharge and home anticoagulant treatment. 
An overview of these points is provided in Figure 1.
The 2019 update of the pulmonary embolism guide-
lines of the European Society of Cardiology (ESC), devel-
oped in cooperation with the European Respiratory 
Society, reinforced the concept that the two pillars of risk 
stratification are the pre-existing health status, i.e. the 
presence of major comorbidities, and the severity of pul-
monary embolism itself.3 Together, they allow clinicians 
to estimate the individual patient’s potential to deteriorate 
despite apparent initial haemodynamic compensation. 
Comorbidities may independently increase the individual 
risk of death or affect the capacity for haemodynamic 
compensation. The severity of pulmonary embolism itself 
is reflected by the degree of haemodynamic compromise 
that vascular obstruction causes.
In this issue of the European Heart Journal – Acute 
Cardiovascular Care, readers will find four studies contrib-
uting valuable information on key risk stratification con-
cepts covering almost the whole spectrum of pulmonary 
embolism severity.4–6 The low-risk end of the spectrum was 
addressed by studies that updated or expanded the 
Pulmonary Embolism Severity Index, the most widely used 
tool for the identification of potential candidates for home 
treatment and low-intensity care. Yamashita et al. found 
that patients from the COntemporary ManageMent AND 
outcomes in patients with Venous ThromboEmbolism 
(COMMAND VTE) registry with a simplified Pulmonary 
Embolism Severity Index ((s)PESI) of zero, indicating low-
risk category, had a reasonably low 30-day mortality: two 
patients out of 383 (0.5%) died due to fatal pulmonary 
embolism and intracranial haemorrhage, respectively.5 
Vedovati and colleagues showed that the use of the respira-
tory index, the ratio of oxygen saturation in air to respira-
tory rate, may help to better identify higher-risk patients at 
risk of imminent decompensation and death.4 They also 
confirmed that the observed 30-day mortality rate among 
patients with (s)PESI=0 was equally low (0.5%) and fur-
ther minimized (0%) after exclusion of patients with signs 
of right ventricular dysfunction according to the latest 2019 
ESC guidelines. This is in line with the conclusions of a 
recent systematic review and meta-analysis7 showing that 
patients with (s)PESI denoting low-risk or, alternatively, 
the absence of all Hestia criteria are characterized by very 
low rates of pulmonary embolism-related complications 
and early deaths, but that only patients without signs of 
right ventricular dysfunction were characterized by a rate 
of complications that was close to zero.
Other studies addressed the challenges posed by inter-
mediate and intermediate-high risk patients. Santos et al. 
reported that, in intermediate-high risk patients with signs 
of right ventricular dysfunction on echocardiography and/
or computed tomographic angiography, the elevation of 
both troponin I and N-terminal pro-brain natriuretic peptide 
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was more strongly associated with all-cause or pulmonary 
embolism-related mortality and rescue thrombolysis than 
the elevation of either cardiac biomarker alone.8 Similarly, 
the single-centre study by Novicic et al. found that the early 
resolution of specific ECG signs present at admission in 
110 intermediate-high and high-risk patients were associ-
ated with better 30-day survival and lower right ventricular 
systolic pressure at discharge.6
Several cohort studies from the past decade focused on 
disease-specific and comorbidity-oriented parameters that 
are strongly associated with early complications after acute 
pulmonary embolism.9 Most of these parameters are patho-
physiologically and clinically interrelated: therefore, it 
does not come as a surprise that different markers of cardio-
pulmonary function are equally good at predicting the 
course of disease. The studies published in the European 
Heart Journal – Acute Cardiovascular Care4–6 remind us 
that pulmonary embolism is a multifaceted condition and a 
comprehensive assessment of organ function, clinical 
parameters and demographic characteristics may also trans-
late into a better risk stratification.
Are we experiencing the final round of this type of 
exploratory research focusing on novel parameters, or their 
combinations into models, for risk stratification of acute 
pulmonary embolism? In the literature there is a worrying 
abundance of successful prediction models and classifiers. 
In most cases, their conclusions have indicated that they 
may provide some type of benefit compared with prior ones 
simply because they asked too much of the available data, 
possibly leading to overfitting and overly optimistic esti-
mates. Only a few studies investigated the impact of the 
implementation of specific models or parameters to drive 
clinical practice. Ideally, this should be tested in terms of 
clinical effectiveness, feasibility and costs. The interven-
tional setting would allow for evaluation of whether the 
classification of patients into a risk category truly corre-
sponds to a specific risk class and, ultimately, if an inter-
vention chosen accordingly can improve their outcome.
A successful example of this process was the assessment 
of scores or combination of criteria designed to identify 
low-risk patients with acute pulmonary embolism who 
should be considered for early discharge and ambulatory 
anticoagulant treatment.1,2 After their development in care-
fully designed and preferentially multi-centre observational 
studies not unlike those presented in this issue,10 ad-hoc 
management studies or randomized controlled trials11–14 led 
to the updated recommendations of international guide-
lines.3 Ongoing research (Clinical Trials identifiers 
NCT02811237, NCT03002467) is testing whether the 
spectrum of patients who may be considered for outpatient 
management can be further expanded. In the very near 
future, physicians will be able to decide on home treatment 
Figure 1. Risk stratification of patients with acute pulmonary embolism: key elements in the year 2020.
Validated clinical tools to identify low-risk patients with pulmonary embolism include the (simplified) Pulmonary Embolism Severity Index ((s)PESI) 
and the Hestia criteria. Haemodynamic instability at presentation is defined in the presence of a systolic blood pressure <90 mm Hg, or a drop by 
⩾40 mm Hg, for >15 min, not caused by new arrhythmia, hypovolaemia, sepsis. The figure was adapted and modified from the Illustrated State-of-
the-Art Capsules prepared by the speakers of the International Society on Thrombosis and Haemostasis 2019 Congress.16 ICU: intensive care unit. 
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of acute pulmonary embolism based on validated treatment 
schemes and scores, adopting those that better suit the care 
setting where they operate.
In the next ride on the merry-go-round, we will hopefully 
witness the evaluation of novel, and possibly safer, reperfu-
sion strategies for selected normotensive patients at a higher 
risk of decompensation.1,2,15 This zone of the severity spec-
trum now represents the highest-priority point of the 
research agenda and may have profound impact on defining 
the standard of treatment of acute pulmonary embolism.
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